3 July 2018 - The EMA has approved a label extension for UCB’s Cimzia allowing its use to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

The approval makes Cimzia (certolizumab pegol), the first Fc-free, PEGylated anti-TNF treatment option for use in moderate-to-severe plaque psoriasis “and marks the entry of UCB into immuno-dermatology, where significant unmet need currently exists,” the firm noted.

The CIMPASI-1 and -2 and CIMPACT trials confirmed the efficacy and safety of the drug in this setting.

Read Pharma Times article